Health committee  In the context of one dose could work, that's different from saying it would work. We do have preliminary evidence to say that there is high efficacy following one dose, but we need more data to understand the durability of that effectiveness and whether or not it wanes. So that's why the discussion around the dose interval remains very alive in the scientific community, and that's why NACI will be looking at that again next week at their meeting.

Health committee  I'm just trying to think about whether we've received data on the effect of the variant from the one dose. I'd have to check on that and get back to you. I don't want to misspeak.

Health committee  I would say that these remain open questions. As public health professionals, we are looking carefully at the science and trying to understand what the impact of variants will be. We need more data from countries that are doing research in this area. Those data are starting to come to us, and we're analyzing those carefully.

Health committee  The latter question is a regulatory question, which belongs to our colleagues at Health Canada. As for the former question, on age groups, it depends on the population being studied, but we do have data from older age groups.

Health committee  It crosses the spectrum of ages, and that's what we'll see and what NACI will see next week as it receives further follow-up data on these populations.

Health committee  I see the chair is showing a red sign.

Health committee  As Dr. Quach said earlier, research is under way now to look at the impact of interchangeability of vaccines and at the durability of the effect of immunization. They are becoming available very quickly. As you said, NACI will be looking at more data from the U.K. next week, and so we and the world are gathering and assessing information on dose schedule on a real-time basis so we can be equipped to make those kinds of recommendations.

Health committee  There are already immunization registries that are used across the country in every jurisdiction, including one that is now being developed in Nunavut with support from the Public Health Agency of Canada. Those are electronic databases that capture information on immunization on a per-individual basis.

Health committee  We'll come back to you with those data.

Health committee  By next week.

Health committee  We will get back with that for sure. None of us on the call today have been directly implicated in that, so I think it best for us to ensure we go back to our quarantine group and ensure that you get that information.

Health committee  From the perspective of undertaking an immunization campaign this large and complex, I know that everybody in this room knows that this is unprecedented for us. What isn't unprecedented is the fact that we work really hard with provinces and territories and with public health officials across the country every day on preparedness and on execution.

Health committee  I would say only that that is a question for the regulatory authority at Health Canada and one, of course, that we can take back and ensure you receive an answer to.

Health committee  I will refer that to Dr. Poliquin on the testing question, please.

Health committee  We'll have to get back to you with the exact numbers on that. I don't have them in my notes at this point in time, but it's easy for us to bring that back to you very quickly.